Tumor necrosis factor

Growth Factors and Cytokines in Health and Disease

Volumn 2, Issue C, 1997, Pages 669-726

  Grell, Matthias ^a   Scheurich, Peter ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957026155     PISSN: 18745687     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5687(97)80038-9     Document Type: Review

References (376)

1. + HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein. Eur. J. Immunol. 20 (1990) 369-377
2. Abe Y., Gatanaga M., Osuka Y., Kimura S., Burger R.A., Granger G.A., and Gatanaga T. Role of 55- and 75-kDa tumor necrosis factor membrane receptors in the regulation of intercellular adhesion molecules-1 expression by HL-60 human promyelocytic leukemia cells in vitro. J. Immunol. 150 (1993) 5070-5079
3. Aderka D., Holtmann H., Toker L., Hahn T., and Wallach D. Tumor necrosis factor induction by Sendai virus. J. Immunol. 136 (1986) 2938-2942
4. Aderka D., Engelmann H., Maor Y., Brakebusch C., and Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175 (1992) 323-329
5. Aderka D., Wysenbeek A., Engelmann H., Cope A.P., Brennan F., Molad Y., Hornik V., Levo Y., Maini R.N., and Feldmann M. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 36 (1993) 1111-1120
6. Adolf G.R., and Apfler I. A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60 kDa TNF receptor, in biological fluids. J. Immunol. Meth. 143 (1991) 127-136
7. Aggarwal B.B., and Eessalu T.E. Effect of phorbol esters on down-regulation and redistribution of cell surface receptors for tumor necrosis factor-alpha. J. Biol. Chem. 262 (1987) 16450-16455
8. Aggarwal B.B., Kohr W.J., Hass P.E., Moffat B., Spencer S.A., Henzel W.J., Bringman T.S., Nedwin G.E., Goeddel D.V., and Harkins R.N. Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem. 260 (1985) 2345-2354
9. Aggarwal B.B., Eessalu T., and Hass P.E. Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon. Nature 318 (1985) 665-667
10. Aggarwal B.B., Graff K., Samal B., Higuchi M., and Liao W.S. Regulation of two forms of the TNF receptors by phorbol ester and dibutyryl cyclic adenosine 3′5,′-monophosphate in human histiocytic lymphoma cell line U-937. Lymphokine Cytokine Res. 12 (1993) 149-158
11. Alzani R., Corti A., Grazioli L., Cozzi E., Ghezzi P., and Marcucci F. Suramin induces deoligomerization of human tumor necrosis factor alpha. J. Biol. Chem. 268 (1993) 12526-12529
12. Amiri P., Locksley R.M., Parslow T.G., Sadick M., Rector E., Ritter D., and McKerrow J.H. Tumour necrosis factor alpha restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice. Nature 356 (1992) 604-607
13. Andersson U., Adolf G., Dohlsten M., Moller G., and Sjogren H.O. Characterization of individual tumor necrosis factor alpha-and beta-producing cells after polyclonal T cell activation. J. Immunol. Meth. 123 (1989) 233-240
14. Arata S., Newton C., Klein T.W., Yamamoto Y., and Friedman H. Legionella pneumophila induced tumor necrosis factor production in permissive versus nonpermissive macrophages. Proc. Soc. Exp. Biol. Med. 203 (1993) 26-29
15. Asher A.L., Mule J.J., Kasid A., Restifo N.P., Salo J.C., Reichert C.M., Jaffe G., Fendly B., Kriegler M., and Rosenberg S.A. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146 (1991) 3227-3234
16. Atkinson Y.H., Marasco W.A., Lopez A.F., and Vadas M.A. Recombinant human tumor necrosis factor-alpha. Regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils. J. Clin. Invest. 81 (1988) 759-765
17. Austgulen R., Espevik T., and Nissen-Meyer J. Fibroblast growth-stimulatory activity released from human monocytes. The contribution of tumour necrosis factor. Scand. J. Immunol. 26 (1987) 621-629
18. 2 production in resting macrophages. Biochem. Biophys. Res. Commun. 136 (1986) 94-101
19. Baker E., Chen L.Z., Smith C.A., Callen D.F., Goodwin R., and Sutherland G.R. Chromosomal location of the human tumor necrosis factor receptor genes. Cytogenet. Cell Genet. 57 (1991) 117-118
20. Baker D., Butler D., Scallon B.J., Oneill J.K., Turk J.L., and Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24 (1994) 2040-2048
21. Baldwin R.L., Chang M.P., Bramhall J., Graves S., Bonavida B., and Wisnieski B.J. Capacity of tumor necrosis factor to bind and penetrate membranes is pH-dependent. Scand. J. Immunol. 141 (1988) 2352-2357
22. Balkwill F.R., Lee A., Aldam G., Moodie E., Thomas J.A., Tavernier J., and Fiers W. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res. 46 (1986) 3990-3993
23. Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.J., Broger C., Loetscher H., and Lesslauer W. Crystal structure of the soluble human 55 kDa TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell 73 (1993) 431-445
24. Barbara J.A., Smith W.B., Gamble J.R., Van Ostade X., Vandenabeele P., Tavernier J., Fiers W., Vadas M.A., and Lopez A.F. Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J. 13 (1994) 843-850
25. Bazan J.F. Emerging families of cytokines and receptors. Curr. Biol. 3 (1993) 603-606
26. Benvenuto R., Paroli M., Buttinelli C., Franco A., Barnaba V., Fieschi C., and Balsano F. Tumour necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis. Clin. Exp. Immunol. 84 (1991) 97-102
27. Beresini M.H., Lempert M.J., and Epstein L.B. Overlapping polypeptide induction in human fibroblasts in response to treatment with interferon-alpha, interferon-gamma, interleukin 1 alpha, interleukin 1 beta, and tumor necrosis factor. J. Immunol. 140 (1988) 485-493
28. Bermudez L.E., and Young L.S. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J. Immunol. 140 (1988) 3006-3013
29. Bermudez L.E., Wu M., and Young L.S. Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor. Lymphokine Res. 9 (1990) 137-145
30. Beutler B., and Cerami A. The biology of cachectin/TNF- a primary mediator of the host response. Annu. Rev. Immunol. 7 (1989) 625-655
31. Beutler B., and van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 264 (1994) 667-668
32. Beutler B., Mahoney J., Le Trang N., Pekala P., and Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J. Exp. Med. 161 (1985) 984-995
33. Beutler B., Milsark I.W., and Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229 (1985) 869-871
34. Beutler B., Krochin N., Milsark I.W., Luedke C., and Cerami A. Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science 232 (1989) 977-980
35. Bevilacqua M.P., Pober J.S., Mendick D.L., Cotran R.S., and Gimbrone Jr. M.A. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc. Natl. Acad. Sci. USA 84 (1987) 9238-9248
36. Bevilacqua M.P., Stengelin S., Gimbrone Jr. M.A., and Seed B. Endothelial leukocyte adhesion molecule 1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science. 243 (1989) 1160-1165
37. Beyaert R., and Fiers W. Molecular mechanisms of tumor necrosis factor-induced cytotoxicity-What we do understand and what we do not. FEBS Lett. 340 (1994) 9-16
38. Billard C., Sigaux F., and Wietzerbin J. IFN-alpha in vivo enhances tumor necrosis factor receptor levels on hairy cells. J. Immunol. 145 (1990) 1713-1718
39. Bigda J., Beletsky I., Brakebusch C., Varfolomeev Y., Engelmann H., Bigda J., Holtmann H., and Wallach D. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J. Exp. Med. 180 (1994) 445-460
40. Blanchard D.K., Djeu J.Y., Klein T.W., Friedman H., and Stewart II W.E. Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J. Leuk. Biol. 43 (1988) 429-435
41. Blanchard D.K., Friedman H., Klein T.W., and Djeu J.Y. Induction of interferon-gamma and tumor necrosis factor by Legionella pneumophila: Augmentation of human neutrophil bactericidal activity. J. Leuk. Biol. 45 (1989) 538-545
42. Blankenstein T., Qin Z.H., Uberla K., Muller W., Rosen H., Volk H.D., and Diamantstein T. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J. Exp. Med. 173 (1991) 1047-1052
43. Blenis J. Signal transduction via the MAP kinases: Proceed at your own RSK. Proc. Natl. Acad. Sci. USA 90 (1993) 5889-5892
44. Boldin M.P., Goncharov T.M., Goltsev Y.V., and Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85 (1996) 803-815
45. Boussiotis V.A., Nadler L.M., Strominger J.L., and Goldfield A.E. Tumor necrosis factor MBOL 97 "Symbol" is an autocrine growth factor for normal human B cells. Proc. Natl. Acad. Sci. USA 91 (1994) 7007-7011
46. Bradbury M.G., and Moreno C. Effect of lipoarabinomannan and mycobacteria on tumour necrosis factor production by different populations of murine macrophages. Clin. Exp. Immunol. 94 (1993) 57-63
47. Brahn E., Peacock D.J., Banquerigo M.L., and Liu D.Y. Effects of tumor necrosis factor alpha (TNF-alpha) on collagen arthritis. Lymphokine Cytokine Res. 11 (1992) 253-256
48. Brakebusch C., Nophar Y., Kemper O., Engelmann H., and Wallach D. Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J. 11 (1992) 943-950
49. Breder C.D., Hazuka C., Ghayur T., Klug C., Huiginin M., Yasuda K., Teng M., and Saper C.B. Regional induction of tumor necrosis Factor Alpha expression in the mouse brain after systemic lipopolysaccharide administration. Proc. Natl. Acad. Sci. USA 91 (1994) 11393-11397
50. Brennan F.M., Chantry D., Jackson A., Maini R., and Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 2 (1989) 244-247
51. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., Hunziker W., Lesslauer W., and Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 87 (1990) 3127-3131
52. Butcher G.A., Garland T., Ajdukiewicz A.B., and Clark I.A. Serum tumor necrosis factor associated with malaria in patients in the Solomon Islands. Trans. R. Soc. Trop. Med. Hyg. 84 (1990) 658-661
53. Cadranel J., Philippe C., Perez J., Milleron B., Akoun G., Ardaillou R., and Baud L. In vitro production of tumour necrosis factor and prostaglandin E2 by peripheral blood mononuclear cells from tuberculosis patients. Clin. Exp. Immunol. 81 (1990) 319-324
54. Camussi G., Bussolino F., Salvidio G., and Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J. Exp. Med. 166 (1987) 1390-1404
55. Camussi G., Tetta C., Bussolino F., Turello E., Brentjens J., Montrucchio G., and Andres G. Effect of leukocyte stimulation on rabbit immune complex glomerulonephritis. Kidney Int. 38 (1990) 1047-1055
56. Cannistra S.A., Vellenga E., Groshek P., Rambaldi A., and Griffin J.D. Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood. 71 (1988) 672-676
57. Carroll M.C., Katzman P., Alicot E.M., Koller B.H., Geraghty D.E., Orr H.T., Strominger J.L., and Spies T. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc. Natl. Acad. Sci. USA 84 (1987) 8535-8539
58. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72 (1975) 3666-3670
59. Chambaut-Guerin A.M., and Thomopoulos P. Regulation by dexamethasone and 1,25-dihydroxyvitamin D3 of the 75 kD-type A tumor necrosis factor receptor surface expression and mRNA level in human U937 cells. Eur. Cytokine Netw. 2 (1991) 355-360
60. Chantry D., Turner M., Abney E., and Feldmann M. Modulation of cytokine production by transforming growth factor-beta. J. Immunol. 142 (1989) 4295-4300
61. Chen S.H., Oakes J.E., and Lausch R.N. Synergistic anti-HSV effect of tumor necrosis factor alpha and interferon gamma in human corneal fibroblasts is associated with interferon beta induction. Antiviral. Res. 22 (1993) 15-29
62. Cheng G., and Baltimore D. TANK, a co-inducer with TRAF-2 of TNF- and CD40L-mediated NF-κB activation. Genes Develop. 10 (1996) 963-973
63. Chollet-Martin S., Montravers P., Gibert C., Elbim C., Desmonts J.M., Fagon J.Y., and Gougerot-Pocidalo M.A. High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect. Immun. 61 (1993) 4553-4559
64. Chu C.Q., Field M., Feldmann M., and Maini R.N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34 (1991) 1125-1132
65. Clark I.A., Cowden W.B., Butcher G.A., and Hunt N.H. Possible roles of tumor necrosis factor in the pathology of malaria. American. J. Pathol. 129 (1987) 192-199
66. Clauss M., Ryan J., and Stern D. Modulation of endothelial cell hemostatic properties by TNF: Insights into the role of endothelium in the host response to inflammatory stimuli. In: Beutler B. (Ed). Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine (1992), Raven Press, New York and Basel 49-63
67. Coley W.B. The treatment of malignent tumors by repeated inoculations of erysipelas; with a report of ten original cases. Am. J. Med. Sci. 105 (1893) 487-511
68. Coley W.B. The therapeutic value of the mixed toxins of the streptococcus of erysipelas in the treatment of inoperable malignant tumors, with a report of 100 cases. Am. J. Med. Sci. 112 (1896) 251-281
69. Cornelius P., Enerback S., Bjursell G., Olivecrona T., and Pekala P.H. Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor. Biochem. J. 249 (1988) 765-769
70. Corti A., Fassina G., Marcucci F., Barbanti E., and Cassani G. Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem. J. 284 (1992) 905-910
71. Creasey A.A., Reynolds M.T., and Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factors. Cancer Res. 46 (1986) 5687-5690
72. Crowe P.D., Van Arsdale T.L., Goodwin R.G., and Ware C.F. Specific induction of 80-kDa tumor necrosis factor receptor shedding in T-Lymphocytes involves the cytoplasmic domain and phosphorylation. J. Immunol. 151 (1993) 6882-6890
73. Crowe P.D., Van Arsdale T.L., Walter B.N., Ware C.F., Hession C., Ehrenfels B., Browning J.L., Din W.S., Goodwin R.G., and Smith C.A. A lymphotoxin-beta-specific receptor. Science 264 (1994) 707-710
74. Cseh K., and Beutler B. Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein. J. Biol. Chem. 264 (1989) 16256-16260
75. Cuturi M.C., Murphy M., Costa-Giomi M.P., Weinmann R., Perussia B., and Trinchieri G. Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J. Exp. Med. 165 (1987) 1581-1594
76. Darnay B.G., Reddy S.A.G., and Aggarwal B.B. Identification of a protein kinase associated with the cytoplasmic domain of the p60 tumor necrosis factor receptor. J. Biol. Chem. 269 (1994) 20299-20304
77. Darnay B.G., Reddy S.A.G., and Aggarwal B.B. Physical and functional association of a serine-threonine protein kinase to the cytoplasmic domain of the p80 form of the human tumor necrosis factor receptor in human histiocytic lymphoma U-937 cells. J. Biol. Chem. 269 (1994) 19687-19690
78. Dayer J.M. Chronic inflammatory joint diseases: Natural inhibitors of interleukin 1 and tumor necrosis factor alpha. J. Rheumatol. Suppl. 27 (1991) 71-75
79. De Valck D., Beyaert R., Van Roy F., and Fiers W. Tumor necrosis factor cytotoxicity is associated with phospholipase D activation. Eur. J. Biochem. 212 (1993) 491-497
80. Desiderio J.V., Kiener P.A., Lin P.F., and Warr G.A. Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor alpha. Infect. Immun. 57 (1989) 1615-1617
81. Dett C.A., Gatanaga M., Ininnis E.K., Cappuccini F., Yamamoto R.S., Granger G.A., and Gatanaga T. Enhancement of lymphokine-activated T killer cell tumor necrosis factor receptor mRNA transcription, tumor necrosis factor receptor membrane expression, and tumor necrosis factor/lymphotoxin release by IL-1 beta, IL-4, and IL-6 in vitro. J. Immunol. 146 (1991) 1522-1526
82. Diazmeco M.T., Berra E., Municio M.M., Sanz L., Lozano J., Dominguez I., Diazgolpe V., Delera M.T.L., Alcami J., Paya C.V., Arenzanaseisdedos F., Virelizier J.L., and Moscat J. A dominant negative protein kinase-C zeta-subspecies blocks NF-kappa-B activation. Mol. Cell. Biol. 13 (1993) 4770-4775
83. Digel W., Schoniger W., Stefanic M., Janssen H., Buck C., Schmid M., Raghavachar A., and Porzsolt F. Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood 76 (1990) 1607-1613
84. Dinarello C.A., Cannon J.G., Wolff S.M., Bernheim H.A., Beutler B., Cerami A., Figari F.S., Palladino M.A., and O'Connor J.V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. 163 (1986) 1433-1450
85. Dinarello C.A., Gelfand J.A., and Wolff S.M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. Jama 269 (1993) 1829-1835
86. Djeu J.Y. TNF production by neutrophils. In: Beutler B. (Ed). Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine (1992), Raven Press, New York 531-537
87. Dobrowsky R.T., and Hannun Y.A. Ceramide stimulates a cytosolic protein phosphatase. J. Biol. Chem. 267 (1992) 5048-5051
88. Duerksen-Hughes P., Wold W.S., and Gooding L.R. Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor. J. Immunol. 143 (1989) 4193-4200
89. Eck M.J., and Sprang S.R. The structure of tumor necrosis factor-alpha at 2.6resolution. Implications for receptor binding. J. Biol. Chem. 264 (1989) 17595-17605
90. Eck M.J., Beutler B., Kuo G., Merryweather J.P., and Sprang S.R. Crystallization of trimeric recombinant human tumor necrosis factor (cachectin). J. Biol. Chem. 263 (1988) 12816-12819
91. Eck M.J., Ultsch M., Rinderknecht E., de Vos A.M., and Sprang S.R. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9- resolution. J. Biol. Chem. 267 (1992) 2119-2122
92. Economou J.S., Rhoades K., Essner R., McBride W.H., Gasson J.C., and Morton D.L. Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. J. Exp. Med. 170 (1989) 321-326
93. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F.M., Walker J., Bijl H., Ghrayeb J., and Woody J.W. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36 (1993) 1681-1690
94. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., and Woody J.N. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
95. Elliott M.J., Maini R.N., Feldmann M., Longfox A., Charles P., Bijl H., and Woody J.N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344 (1994) 1125-1127
96. Engelmann H., Holtmann H., Brakebusch C., Avni Y.S., Sarov I., Nophar Y., Hadas E., Leitner O., and Wallach D. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J. Biol. Chem. 265 (1990) 14497-14504
97. Engelmann H., Novick D., and Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J. Biol. Chem. 265 (1990) 1531-1536
98. Erickson S., de Sauvage F.J., Kikly K., Carver-Moore K., Pitts-Meek S., Gillett N., Sheehan K.C.F., Schreiber R.D., Goeddel D.V., and Moore M.W. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372 (1994) 560-563
99. Erikstein B.K., Smeland E.B., Blomhoff H.K., Funderud S., Prydz K., Lesslauer W., and Espevik T. Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes. Eur. J. Immunol. 21 (1991) 1033-1037
100. Espevik T., Figari I.S., Ranges G.E., and Palladino Jr. M.A. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1. J. Immunol. 140 (1988) 2312-2316
101. Evans T.J., Moyes D., Carpenter A., Martin R., Loetscher H., Lesslauer W., and Cohen J. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp. Med. 180 (1994) 2173-2179
102. Fahey III T.J., Sherry B., Tracey K.J., van Deventer S., Jones II W.G., Minei J.P., Morgello S., Shires G.T., and Cerami A. Cytokine production in a model of wound healing: The appearance of MIP-1, MIP-2, cachectin/TNF and IL-1. Cytokine 2 (1990) 92-99
103. Feldmann M., Brennan F.M., Williams R.O., Cope A.P., Gibbons D.L., Katsikis P.D., and Maini R.N. Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. Prog. Growth Factor Res. 4 (1992) 247-255
104. Ferran C., Dautry F., Merite S., Sheeman K., Schreiber R., Grau G., Bach J.-F., and Chatenoud L. Anti-tumor necrosis factor modulates anti-CD3-triggerd T cell cytokine gene expression in vivo. J. Clin. Invest. 93 (1994) 2189-2196
105. Fishman M. Cytolytic activities of activated macrophages versus paraformaldehyde-fixed macrophages; soluble versus membrane-associated TNF. Cell. Immunol. 137 (1991) 164-174
106. Franciotta D.M., Grimaldi L.M., Martino G.V., Piccolo G., Bergamaschi R., Citterio A., and Melzi d'Eril G.V. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol. 26 (1989) 787-789
107. Fraser A., and Evan G. A license to kill. Cell 85 (1996) 781-784
108. Frei III E., and Spriggs D. Tumor necrosis factor: Still a promising agent. J. Clin. Oncol. 7 (1989) 291-294
109. Freund Y.R., Sgarlato G., Jacob C.O., Suzuki Y., and Remington J.S. Polymorphisms in the tumor necrosis factor alpha (TNF-alpha) gene correlate with murine resistance to development of toxoplasmic encephalitis and with levels of TNF-alpha mRNA in infected brain tissue. J. Exp. Med. 175 (1992) 683-688
110. Fuchs P., Strehl S., Dworzak M., Himmler A., and Ambros P.F. Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13. Genomics 13 (1992) 219-224
111. Furman W.L., Strother D., McClain K., Bell B., Leventhal B., and Pratt C.B. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: A Pediatric Oncology Group study. J. Clin. Oncol. 11 (1993) 2205-2210
112. Gamble J.R., Harlan J.M., Klebanoff S.J., and Vadas M.A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl. Acad. Sci USA 82 (1985) 8667-8671
113. Gamble J.R., Smith W.B., and Vadas M.A. TNF modulation of endothelial and neutrophil adhesion. In: Beutler B. (Ed). Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine (1992), Raven Press, New York 65-86
114. Gatanaga T., Hwang C.D., Kohr W., Cappuccini F., Lucci III J.A., Jeffes E.W., Lentz R., Tomich J., Yamamoto R.S., and Granger G.A. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc. Natl. Acad. Sci. USA 87 (1990) 8781-8784
115. Gatanaga T., Hwang C.D., Gatanaga M., Cappuccini F., Yamamoto R.S., and Granger G.A. The regulation of TNF receptor mRNA synthesis, membrane expression, and release by PMA- and LPS-stimulated human monocytic THP-1 cells in vitro. Cell. Immunol. 138 (1991) 1-10
116. Gearing A.J.H., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., Drummond A.H., Galloway W.A., Gilbert R., Gordon J.L., Leber T.M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Wells G., Wood L.M., and Woolley K. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370 (1994) 555-557
117. Gehr G., Gentz R., Brockhaus M., Loetscher H., and Lesslauer W. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J. Immunol. 149 (1992) 911-917
118. Gessani S., Johnson S.E., McCandless S., and Baglioni C. The antiviral activity of tumor necrosis factor in HeLa cells is not mediated by interferons. Studies with TNF-resistant variants. J. Biol. Regul. Homeost. Agents 2 (1988) 139-144
119. Ghiara P., Boraschi D., Nencioni L., Ghezzi P., and Tagliabue A. Enhancement of in vivo immune response by tumor necrosis factor. J. Immunol. 139 (1987) 3676-3679
120. Gifford G.E., and Lohmann-Matthes M.L. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J. Natl. Cancer Inst. 78 (1987) 121-124
121. Goodwin R.G., Anderson D., Jerzy R., Davis T., Brannan C.I., Copeland N.G., Jenkins N.A., and Smith C.A. Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor. Mol. Cell. Biol. 11 (1991) 3020-3026
122. Grau G.E., Fajardo L.F., Piquet P.-F., Allet B., Lambert P.-H., and Vasalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237 (1987) 1210-1212
123. Grau G.E., Heremans H., Piguet P.F., Pointaire P., Lambert P.H., Billiau A., and Vassalli P. Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc. Natl. Acad. Sci. USA 86 (1989) 5572-5574
124. Grau G.E., Taylor T.E., Molyneux M.E., Wirima J.J., Vassalli P., Hommel M., and Lambert P.H. Tumor necrosis factor and disease severity in children with falciparum malaria. N. Engl. J. Med. 320 (1989) 1586-1591
125. Grell M., Scheurich P., Meager A., and Pfizenmaier K. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res. 12 (1993) 143-148
126. Grell M., Zimmermann G., Hülser D., Pfizenmaier K., and Scheurich P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J. Immunol. 153 (1994) 1963-1972
127. Grell M., Douni E., Wajant H., Löhden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., and Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDA tumor necrosis factor receptor. Cell 83 (1995) 793-802
128. Gresser I., Belardelli F., Maury C., Tovey M.G., and Maunoury M.T. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. Int. J. Cancer 38 (1986) 251-257
129. Guy G.R., Cao X., Chua S.P., and Tan Y.H. Okadaic acid mimics multiple changes in early protein phosphorylation and gene expression induced by tumor necrosis factor or interleukin-1. J. Biol. Chem. 267 (1992) 1846-1852
130. Hackett R.J., Davis L.S., and Lipsky P.E. Comparative effects of tumor necrosis factor-alpha and IL-1 beta on mitogen-induced T cell activation. J. Immunol. 140 (1988) 2639-2644
131. Haliday E.M., Ramesha C.S., and Ringold G. TNF induces c-fos via a novel pathway requiring conversion of arachidonic acid to a lipoxygenase metabolite. EMBO J. 10 (1991) 109-115
132. Han J., Thompson P., and Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172 (1990) 391-394
133. Hanemaaijer R., Koolwijk P., le Clercq L., de Vree W.J., and van Hinsbergh V.W. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem. J. 296 (1993) 803-809
134. Hannun Y.A. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269 (1994) 3125-3128
135. Haranaka K. Tumor necrosis factor: How to improve the antitumor activity and decrease accompanying side effects for therapeutic application. J. Biol. Response Mod. 7 (1988) 525-534
136. Haskard D., Cavender D., Beatty P., Sprninger T., and Ziff M. T lymphocyte adhesion to endothelial cells: Mechanisms demonstrated by anti-LFA-1 antibodies. J. Immunol 137 (1986) 2901-2906
137. Hauser S.L., Doolittle T.H., Lincoln R., Brown R.H., and Dinarello C.A. Cytokine accumulations in CSF of multiple sclerosis patients: Frequent detection of IL-1 and TNF but not IL-6. Neurology 40 (1991) 1735-1739
138. Havell E.A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J. Immunol. 143 (1989) 2894-2899
139. Havell E.A. Listeria monocytogenes-induced interferon-gamma primes the host for production of tumor necrosis factor and interferon-alpha/beta. J. Infect. Dis. 167 (1993) 1364-1371
140. Havell E.A., Fiers W., and North R.J. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med. 167 (1988) 1967-1985
141. 2 is crucial in the cytotoxic action of tumor necrosis factor. J. Biol. Chem. 268 (1993) 11290-11295
142. Heller R.A., and Krönke M. Tumor necrosis factor receptor-mediated signaling pathways. J. Cell Biol. 126 (1994) 5-9
143. Heller R.A., Song K., Fan N., and Chang D.J. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 70 (1992) 47-56
144. Hensel G., Meichle A., Pfizenmaier K., and Krönke M. PMA-responsive 5′ flanking sequences of the human TNF gene. Lymphokine Res. 8 (1989) 347-351
145. Higuchi M., and Aggarwal B.B. Okadaic acid induces down-modulation and shedding of tumor necrosis factor receptors. Comparison with another tumor promoter, phorbol ester. J. Biol. Chem. 268 (1993) 5624-5631
146. Higuchi M., and Aggarwal B.B. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J. Immunol. 152 (1994) 3550-3558
147. Himmler A., Maurer-Fogy I., Krönke M., Scheurich P., Pfizenmaier K., Lantz M., Olsson I., Hauptmann R., Stratowa C., and Adolf G.R. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. DNA Cell. Biol. 9 (1990) 705-715
148. Hohmann H.P., Remy R., Brockhaus M., and van Loon A.P.G.M. Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J. Biol. Chem. 264 (1989) 14927-14934
149. Hori T., Kashiyama S., Oku N., Hayakawa M., Shibamoto S., Tsujimoto M., Nishihara T., and Ito F. Effects of tumor necrosis factor on cell growth and expression of transferrin receptors in human fibroblasts. Cell Struct. Funct. 13 (1988) 425-433
150. Howard O.M.Z., Clouse K.A., Smith C., Goodwin R.G., and Farrar W.L. Soluble tumor necrosis factor receptor-inhibition of human immunodeficiency virus activation. Proc. Natl. Acad. Sci. USA 90 (1993) 2335-2339
151. Hsu H., Xiong J., and Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 81 (1995) 495-504
152. Hsu H., Shu H.-B., Pan M.-G., and Goeddel D.V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84 (1996) 299-308
153. Hsu H., Huang J., Shu H.-B., Baichwal V., and Goeddel D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4 (1996) 387-396
154. Hu F.-Q., Goodwin R.G., Davis T., Pickup D.J., and Smith C.A. Cowpox virus encodes two soluble, secreted forms of TNF receptor. Eur. Cytokine Netw. 5 (1994) 125
155. Hughes T.K., Kaspar T.A., and Coppenhaver D.H. Synergy of antiviral actions of TNF and IFN-gamma: Evidence for a major role of TNF-induced IFN-beta. Antiviral. Res. 10 (1988) 1-9
156. Israel N., Hazan U., Alcami J., Munier A., Arenzana-Seisdedos F., Bachelerie F., Israel A., and Virelizier J.L. Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens. J. Immunol. 143 (1989) 3956-3960
157. Itoh N., Yonehara S., Ishi A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., and Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66 (1991) 233-243
158. Jäättelä M. Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab. Invest. 64 (1991) 724-742
159. 2. J. Immunol. 151 (1993) 4286-4294
160. Jäättelä M., and Wissing D. Heat-shock proteins protect cells from monocyte cytotoxicity: possible mechanism of self-protection. J. Exp. Med. 177 (1993) 231-236
161. Jacob C.O., and McDevitt H.O. Tumour necrosis factor-alpha in murine autoimmune "lupus" nephritis. Nature 331 (1988) 356-358
162. Jelinek D.F., and Lipsky P.E. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. J. Immunol. 139 (1987) 2970-2976
163. Jevnikar A.M., Brennan D.C., Singer G.G., Heng J.E., Maslinski W., Wuthrich R.P., Glimcher L.H., and Kelley V.E. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha. Kidney Int. 40 (1991) 203-211
164. Johnson D.R., and Pober J.S. Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy- and light-chain genes in vascular endothelium. Proc. Natl. Acad. Sci. USA 87 (1990) 5183-5187
165. Jones E.Y., Stuart D.I., and Walker N.P. Structure of tumour necrosis factor. Nature 338 (1989) 225-228
166. Jongeneel C.V. The TNF and lymphotoxin promoters. In: Beutler B. (Ed). Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine (1992), Raven Press, New York 539-559
167. Kagan B.L., Baldwin R.L., Munoz D., and Wisnieski B.J. Formation of ion-permeable channels by tumor necrosis factor-alpha. Science 255 (1992) 1427-1430
168. Kalthoff H., Roeder C., Brockhaus M., Thiele H.G., and Schmiegel W. Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of eath other, up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA. J. Biol. Chem. 268 (1993) 2762-2766
169. Kasid A., Director E.P., Stovroff M.C., Lotze M.T., and Rosenberg S.A. Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells. Cancer Res. 50 (1990) 5072-5076
170. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., and Kollias G. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J. 10 (1991) 4025-4031
171. Kemeny N., Childs B., Larchian W., Rosado K., and Kelsen D. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66 (1990) 659-663
172. Kern P., Hemmer C.J., Van Damme J., Gruss H.J., and Dietrich M. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am. J. Med. 87 (1989) 139-143
173. Kim M.Y., Linardic C., Obeid L., and Hannun Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J. Biol. Chem. 266 (1991) 484-489
174. Kindler V., Sappino A.P., Grau G.E., Piguet P.F., and Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56 (1989) 731-740
175. Klebanoff S.J., Vadas S.A., Harlan J.M., Sparks L.H., Gamble J.R., Agosi J.M., and Waltersdorph A.M. Stimulation of neutrophils by tumor necrosis factor. J. Immunol. 136 (1986) 4220-4225
176. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., Scallon B., Moore M.A., Vilcek J., Daddona P., and Ghrayeb J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30 (1993) 1443-1453
177. Kock A., Schwarz T., Kirnbauer R., Urbanski A., Perry P., Ansel J.C., and Luger T.A. Human keratinocytes are a source for tumor necrosis factor alpha: Evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J. Exp. Med. 172 (1990) 1609-1614
178. r cytosol proteins. Biochem. J. 267 (1990) 91-98
179. Kolesnick R., and Golde D.W. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77 (1994) 325-328
180. Kollias G. Tumour necrosis factor: A specific trigger in arthritis. Res. Immunol. 144 (1993) 342-347
181. Kolls J., Peppel K., Silva M., and Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA 91 (1994) 215-219
182. Kongshavn P.A., and Ghadirian E. Effect of tumor necrosis factor on growth of Trypanosoma musculi in vivo and in vitro. Adv. Exp. Med. Biol. 239 (1988) 257-262
183. Kriegler M., Perez C., DeFay K., Albert I., and Lu S.D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53 (1988) 45-53
184. Krönke M., Hensel G., Schlüter C., Scheurich P., Schütze S., and Pfizenmaier K. Tumor necrosis factor and lymphotoxin gene expression in human tumor cell lines. Cancer Res. 48 (1988) 5417-5421
185. Krönke M., Schütze S., Scheurich P., and Pfizenmaier K. TNF signal transduction and TNF-responsive genes. In: Aggarwal B.B., and Vilcek J. (Eds). Tumor Necrosis Factors: Structure, Function and Mechanism of Action (1992), Marcel Dekker Inc., New York 189-216
186. Kunitani M.G., Cunico R.L., and Staats S.J. Reversible subunit dissociation of tumor necrosis factor during hydrophobic interaction chromatography. J. Chromatogr. 443 (1988) 205-220
187. Kuprash D., Turetskaya R., Boldin M., Udalova I., Kistanova E., Smirnova J., and Nedospasov S. Structure, polymorphism and regulation of tumor necrosis factor genes at genomic loci. In: Fiers W., and Buurman W.A. (Eds). Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance (1993), Karger, New York 19-26
188. Kwiatkowski D. TNF-inducing malaria toxin: A sheep in wolf's clothing?. Ann. Trop. Med. Parasitol. 87 (1993) 613-616
189. Kwiatkowski D., Molyneux M.E., Stephens S., Curtis N., Klein N., Pointaire P., Smit M., Allan R., Brewster D.R., Grau G.E., and Greenwood B.M. Anti-TNF therapy inhibits fever in cerebral malaria. Q. J. Med. 86 (1993) 91-98
190. Kyriakis J.M., Banerjee P., Nikolakaki E., Dai T., Rubie E.A., Ahmad M.F., Avruch J., and Woodgett J.R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369 (1994) 160-165
191. Lancaster Jr. J.R., Laster S.M., and Gooding L.R. Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor. FEBS Lett. 248 (1989) 169-174
192. Langermans J.A., van der Hulst M.E., Nibbering P.H., and van Furth R. Endogenous tumor necrosis factor alpha is required for enhanced antimicrobial activity against Toxoplasma gondii and Listeria monocytogenes in recombinant gamma interferon-treated mice. Infect. Immun. 60 (1992) 5107-5112
193. Lantz M., Gullberg U., Nilsson E., and Olsson I. Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J. Clin. Invest. 86 (1990) 1336-1342
194. Lantz M., Thysell H., Nilsson E., and Olsson I. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J. Clin. Invest. 88 (1991) 2026-2031
195. Laster S.M., Wood J.G., and Gooding L.R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J. Immunol. 141 (1988) 2629-2634
196. Lee J.C., Truneh A., Smith M.F., and Tsang K.J. Induction of interleukin 2 receptor (TAC) by tumor necrosis factor in YT cells. J. Immunol. 139 (1987) 1935-1938
197. Lee M.D., Zentella A., Pekala P.H., and Cerami A. Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. Proc. Natl. Acad. Sci. USA 84 (1987) 2590-2594
198. Lee T.H., Lee G.W., Ziff E.B., and Vilcek J. Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibroblasts. Mol. Cell. Biol. 10 (1990) 1982-1988
199. Lee T.H., Wisniewski H.G., and Vilcek J. A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J. Cell Biol. 116 (1992) 545-557
200. Lee G.W., Lee T.H., and Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J. Immunol. 150 (1993) 1804-1812
201. Lejeune F., Lienard D., Eggermont A., Koops H.S., Rosenkaimer F., Gerain J., Klaase J., Kroon B., Vanderveken J., and Schmitz P. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J. Cell. Biochem. 56 (1994) 52-61
202. Lewis M., Tartaglia L.A., Lee A., Bennett G.L., Rice G.C., Wong G.H., Chen E.Y., and Goeddel D.V. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. USA 88 (1991) 2830-2834
203. Libert C., Takahashi N., Cauwels A., Brouckaert P., Bluethmann H., and Fiers W. Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur. J. Immunol. 24 (1994) 2237-2242
204. Lienard D., Ewalenko P., Delmotte J.J., Renard N., and Lejeune F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10 (1992) 52-60
205. Lienard D., Lejeune F.J., and Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J. Surg. 16 (1992) 234-240
206. 2 is phosphorylated and activated by MAP-kinase. Cell 72 (1993) 269-278
207. + cytolytic T lymphocyte clones. Evidence for a TNF-alpha-independent cytolytic mechanism. J. Immunol. 148 (1992) 3789-3798
208. Liu J., Mathias S., Yang Z.H., and Kolesnick R.N. Renaturation and tumor necrosis factor-alpha stimulation of a 97-kDa ceramide-activated protein kinase. J. Biol. Chem. 269 (1994) 3047-3052
209. Loetscher H., Pan Y.C., Lahm H.W., Gentz R., Brockhaus M., Tabuchi H., and Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61 (1990) 351-359
210. Loetscher H., Stueber D., Banner D., Mackay F., and Lesslauer W. Human tumor necrosis factor-alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J. Biol. Chem. 268 (1993) 26350-26357
211. Lucas R., Magez S., De Leys R., Fransen L., Scheerlinck J.P., Rampelberg M., Sablon E., and De Baetselier P. Mapping the lectin-like activity of tumor necrosis factor. Science 263 (1994) 814-817
212. Luo G., Niesel D.W., Shaban R.A., Grimm E.A., and Klimpel G.R. Tumor necrosis factor alpha binding to bacteria: Evidence for a high-affinity receptor and alteration of bacterial virulence properties. Infect. Immun. 61 (1993) 830-835
213. MacNaul K.L., Chartrain N., Lark M., Tocci M.J., and Hutchinson N.I. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J. Biol. Chem. 265 (1990) 17238-17245
214. Maimone D., Gregory S., Arnason B.G., and Reder A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 32 (1991) 67-74
215. Maini R.N., Brennan F.M., Williams R., Chu C.Q., Cope A.P., Gibbons D., Elliott M., and Feldmann M. TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin. Exp. Rheumatol. 11 (1993) 173-175
216. Manda T., Shimomura K., Mukumoto S., Kobayashi K., Mizoto T., and Hirai O. Recombinant human tumor necrosis factor-alpha: Evidence of an indirect mode of antitumor activity. Cancer Res. 47 (1987) 3707-3711
217. Männel D.N., Moore R.N., and Mergenhager S.E. Macrophages as a major source of tumoricidal activity (tumor necrotizing factor). Infect. Immunol. 30 (1980) 532-539
218. Matsuyama T., Hamamoto Y., Soma G., Mizuno D., Yamamoto N., and Kobayashi N. Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): Enhancement of HIV replication. J. Virol. 63 (1989) 2504-2509
219. Matthews N., Neale M.L., Jackson S.K., and Stark J.M. Tumour cell killing by tumour necrosis factor: Inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism. Immunology 62 (1987) 153-155
220. McGeehan G.M., Becherer J.D., Bast R.C., Boyer C.M., Champion B., Connolly K.M., Conway J.G., Furdon P., Karp S., Kidao S., McElroy A.B., Nichols J., Pryzwansky K.M., Schoenen F., Sekut L., Truesdale A., Verghese M., Warner J., and Ways J.P. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 370 (1994) 558-561
221. Meager A., Leung H., and Woolley J. Assays for tumour necrosis factor and related cytokines. J. Immunol. Meth. 116 (1989) 1-17
222. Meichle A., Schütze S., Hensel G., Brunsing D., and Krönke M. Protein kinase C-independent activation of nuclear factor kappa B by tumor necrosis factor. J. Biol. Chem. 265 (1990) 8339-8343
223. Merrill J.E., Strom S.R., Ellison G.W., and Myers L.W. In vitro study of mediators of inflammation in multiple sclerosis. J. Clin. Immunoly. 9 (1989) 84-96
224. Mestan J., Brockhaus M., Kirchner H., and Jacobsen H. Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2′,5′-adenylate synthetase. J. Gen. Virol. 69 (1988) 3113-3120
225. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., Cerami A., Wolff S.M., and Wilmore D.W. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318 (1988) 1481-1486
226. Michihiko S., Yamamoto N., Shinozaki F., Shimada K., Soma G., and Kobayashi N. Augmentation of in vitro HIV replication in peripheral blood mononuclear cells of AIDS and ARC patients by tumour necrosis factor. Lancet 1 (1989) 1206-1207
227. Mirzabekov T., Baldwin R.L., Kagan B.L., and Wisnieski B.J. The pH-dependent step of TNFα and TNF-β channel activity is bilayer insertion. Eur. Cytokine Netw. 5 (1994) 87
228. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., Madani H., and Widmer M.B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151 (1993) 1548-1561
229. Mohler K.M., Sleath P.R., Fitzner J.N., Cerretti D.P., Alderson M., Kerwar S.S., Torrance D.S., Ottenevans C., Greenstreet T., Weerawarna K., Kronheim S.R., Petersen M., Gerhart M., Kozlosky C.J., March C.J., and Black R.A. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370 (1994) 218-220
230. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177 (1993) 1675-1680
231. Muchmore A., Decker J., Shaw A., and Wingfield P. Evidence that high mannose glycopeptides are able to functionally interact with recombinant tumor necrosis factor and recombinant interleukin 1. Cancer Res. 50 (1990) 6285-6290
232. Müller R., Marmenout A., and Fiers W. Synthesis and maturation of recombinant human tumor necrosis factor in eukaryotic systems. FEBS Lett. 197 (1986) 99-104
233. Müller G., Ajoub M., Storz P., Renneke J., Fabbro D., and Pfizenmaier K. PKC ζ is a molecular switch in signal transduction of TNF-α, bifunctionally regulated by ceramide and arachidonic acid. EMBO J. 14 (1995) 1961-1969
234. Mundy G.R. Hypercalcemic factors other than parathyroid hormone-related protein. Endocrinol. Metab. Clin. North Am. 18 (1989) 795-806
235. Mundy G.R., Roodman G.D., Bonewald L.F., Yoneda T., and Sabatini M. Effects of TNF and lymphotoxin on bone cells. Immunol. Ser. 56 (1992) 483-498
236. Munker R., Gasson J., Ogawa M., and Koeffler H.P. Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature 323 (1986) 79-82
237. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J.D., Zhang M., Gentz R., Mann M., Krammer P.H., Peter M.E., and Dixit V.M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85 (1996) 817-827
238. Nagata S. Mutations in the Fas antigen gene in lpr mice. Semin. Immunol. 6 (1994) 3-8
239. Nakane A., Minagawa T., and Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect. Immun. 56 (1988) 2563-2569
240. Nakane A., Numata A., and Minagawa T. Endogenous tumor necrosis factor, interleukin-6, and gamma interferon levels during Listeria monocytogenes infection in mice. Infect. Immun. 60 (1992) 523-528
241. Naotunne T.S., Karunaweera N.D., Del Giudice G., Kularatne M.U., Grau G.E., Carter R., and Mendis K.N. Cytokines kill malaria parasites during infection crisis: Extracellular complementary factors are essential. J. Exp. Med. 173 (1991) 523-529
242. Nargi F.E., and Yang T.J. Optimization of the L-M cell bioassay for quantitating tumor necrosis factor alpha in serum and plasma. J. Immunol. Meth. 159 (1993) 81-91
243. Nawroth P.P., Bank I., Handley D., Cassimeris J., Chess L., and Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 163 (1986) 1363-1375
244. Nedwin G.E., Naylor S.L., Sakaguchi A.Y., Smith D., Jarrett-Nedwin J., Pennica D., Goeddel D.V., and Gray P.W. Human lymphotoxin and tumor necrosis factor genes: Structure, homology and chromosomal localization. Nucleic Acids Res. 13 (1985) 6361-6373
245. 2 by p42-microtubule-associated protein 2 kinase and protein kinase C. J. Biol. Chem. 268 (1993) 1960-1964
246. Nokta M., Matzke D., Jennings M., Schlick E., Nadler P.I., and Pollard R. In vivo administration of tumor necrosis factor-alpha is associated with antiviral activity in human peripheral mononuclear cells. Proc. Soc. Exp. Biol. Med. 197 (1991) 144-149
247. Nussler A., Pied S., Goma J., Renia L., Miltgen F., Grau G.E., and Mazier D. TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6. Int. Immunol. 3 (1991) 317-321
248. Obeid L.M., Linardic C.M., Karolak L.A., and Hannun Y.A. Programmed cell death induced by ceramide. Science 259 (1993) 1769-1771
249. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M., Richards S., Dhein J., Trauth B.C., Ponsting H., and Krammer P.H. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 267 (1992) 10709-10715
250. Ohno K., Nakano T., Matsumoto Y., Watari T., Goitsuka R., Nakayama H., Tsujimoto H., and Hasegawa A. Apoptosis induced by tumor necrosis factor in cells chronically infected with feline immunodeficiency virus. J. Virol. 67 (1993) 2429-2433
251. Orosz P., Echtenacher B., Falk W., Ruschoff J., Weber D., and Männel D.N. Enhancement of experimental metastasis by tumor necrosis factor. J. Exp. Med. 177 (1993) 1391-1398
252. Osborn L., Kunkel S., and Nabel G.J. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc. Natl. Acad. Sci. USA 86 (1989) 2336-2340
253. Osborn L., Hession C., Tizard R., Vassallo C., Luhowskyj S., Chi-Rosso G., and Lobb R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59 (1989) 1203-1211
254. Palladino M.A., Shalaby M.R., Kramer S.M., Ferraiolo B.L., Baughman R.A., Deleo A.B., Crase D., Marafino B., Aggarwal B.B., and Figari I.S. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: Induction of tumor-specific immunity. J. Immunol. 138 (1987) 4023-4032
255. Palombella V.J., Yamashiro D.J., Maxfield F.R., Decker S.J., and Vilcek J. Tumor necrosis factor increases the number of epidermal growth factor receptors on human fibroblasts. J. Biol. Chem. 262 (1987) 1950-1954
256. Paterson P.Y. Autoimmune neurological diseases: experimental animal systems and implications for multiple sclerosis. In: Talel N. (Ed). Autoimmunity: Genetic, Immunologic Virologic, and Clinical Aspects (1977), Academic Press, Basel, Switzerland 643-692
257. Peck R., Brockhaus M., and Frey J.R. Cell surface tumor necrosis factor (TNF) accounts for monocyte- and lymphocyte-mediated killing of TNF-resistant target cells. Cell. Immunol. 122 (1989) 1-10
258. Peck R., Brockhaus M., and Frey J.R. The principal tumor necrosis factor receptor in monocyte cytotoxicity is on the effector cell, not on the target cell. Cell. Immunol. 132 (1991) 308-318
259. Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., Kohr W.J., Aggarwal B.B., and Goeddel D.V. Human tumor necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 312 (1984) 724-729
260. Perez C., Albert I., DeFay K., Zachariades N., Gooding L., and Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63 (1990) 251-258
261. Peters P.M., Ortaldo J.R., Shalaby M.R., Svedersky L.P., Nedwin G.E., Bringman T.S., Hass P.E., Aggarwal B.B., Herberman R.B., and Goeddel D.V. Natural killer-sensitive targets stimulate production of TNFα but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J. Immunol. 137 (1986) 2592-2598
262. Peterson P.K., Gekker G., Chao C.C., Hu S.X., Edelman C., Balfour Jr. H.H., and Verhoef J. Human cytomegalovirus-stimulated peripheral blood mononuclear cells induce HIV-1 replication via a tumor necrosis factor-alpha-mediated mechanism. J. Clin. Invest. 89 (1992) 574-580
263. Pfeffer K., Matsuyama T., Kundig T.M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P.S., Krönke M., and Mak T.W. Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73 (1993) 457-467
264. Pfizenmaier K., Scheurich P., Schlüter C., and Krönke M. Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J. Immunol. 138 (1987) 975-980
265. Pfizenmaier K., Himmler A., Schütze S., Scheurich P., and Krönke M. TNF receptors and TNF signal transduction. In: Beutler B. (Ed). Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine (1992), Raven Press, New York 439-472
266. Philip R., and Epstein L.B. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 323 (1986) 86-89
267. Piguet P.F., Grau G.E., Vesin C., Loetscher H., Gentz R., and Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77 (1992) 510-514
268. Pisa P., Gennene M., Soder O., Ottenhoff T., Hansson M., and Kiessling R. Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J. Infect. Dis. 161 (1990) 988-991
269. Poli G., Kinter A., Justement J.S., Kehrl J.H., Bressler P., Stanley S., and Fauci A.S. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc. Natl. Acad. Sci. USA 87 (1990) 782-785
270. Porteu F., and Hieblot C. Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J. Biol. Chem. 269 (1994) 2834-2840
271. Porteu F., Brockhaus M., Wallach D., Engelmann H., and Nathan C.F. Human neutrophil elastase release a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J. Biol. Chem. 266 (1991) 18846-18853
272. Powell M.B., Mitchell D., Lederman J., Buckmeier J., Zamvil S.S., Graham M., Ruddle N.H., and Steinman L. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int. Immunol. 2 (1990) 539-544
273. Raines M.A., Kolesnick R.N., and Golde D.W. Sphingomyelinase and ceramide activate mitogen-activated protein kinase in myeloid HL-60 cells. J. Biol. Chem. 268 (1993) 14572-14575
274. Ranges G.E., Zlotnik A., Espevik T., Dinarello C.A., Cerami A., and Palladino Jr. M.A. Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J. Exp. Med. 167 (1988) 1472-1478
275. + cytotoxic T-lymphocyte-mediated lysis. J. Immunol. 150 (1993) 4303-4314
276. Remick D.G., Kunkel R.G., Larrick J.W., and Kunkel S.L. Acute in vivo effects of human recombinant tumor necrosis factor. Lab. Invest. 56 (1987) 583-590
277. Robbins D.S., Shirazi Y., Drysdale B.E., Liebermann A., Shin H.S., and Shin M.L. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J. Immunol. 139 (1987) 2593-2597
278. Rodriguez C., Roldan E., Navas G., and Brieva J.A. Essential role of tumor necrosis factor-alpha in the differentiation of human tonsil in vivo induced B cells capable of spontaneous and high-rate immunoglobulin secretion. Eur. J. Immunol. 23 (1993) 1160-1164
279. Rook G.A., Attiyah R.A., and Foley N. The role of cytokines in the immunopathology of tuberculosis, and the regulation of agalactosyl IgG. Lymphokine Res. 8 (1989) 323-328
280. Rothe J., Lesslauer W., Loetscher H., Lang Y., Koebel P., Kontgen F., Althage A., Zinkernagel R., Steinmetz M., and Bluethmann H. Mice lacking the tumour necrosis factor receptor-1 are resistant to TNF-mediated toxicity but highly susceptible to infection by listeria monocytogenes. Nature 364 (1993) 798-802
281. Rothe M., Wong S.C., Henzel W.J., and Goeddel D.V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78 (1994) 681-692
282. Rothe M., Sarma V., Dixit V.M., and Goeddel D.V. TRAF2-mediated activation of BF-κB by TNF receptor 2 and CD40. Science 269 (1995) 1424-1427
283. Rothe M., Pan M.-G., Henzel W.J., Ayres T.M., and Goeddel D. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83 (1995) 1243-1252
284. Rothe M., Xiong J., Shu H.-B., Williamson K., Goddard A., and Goeddel D. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc. Natl. Acad. Sci. USA 93 (1996) 8241-8246
285. Rothstein J.L., and Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc. Natl. Acad. Sci. USA 85 (1988) 607-611
286. Rouzer C., and Cerami A. Hypertriglyceridemia associated with Trypanosoma brucei infection in rabbits: Role of defective triglyceride removal. Mol. Biochem. Parasitol. 2 (1980) 31-37
287. Rubin B.Y., Anderson S.L., Sullivan S.A., Williamson B.D., Carswell E.A., and Old L.J. Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor. J. Exp. Med. 164 (1986) 1350-1355
288. Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., Padula S.J., and Clark R.B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172 (1990) 1193-1200
289. Ruggiero V., Johnston S., and Baglioni C. Protection from tumor necrosis factor cytotoxicity by protease inhibitors. Cell. Immunol. 107 (1987) 317-325
290. Santambrogio L., Hochwald G.M., Saxena B., Leu C.H., Martz J.E., Carlino J.A., Ruddle N.H., Palladino M.A., Gold L.I., and Thorbecke G.J. Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J. Immunol. 151 (1993) 1116-1127
291. Sariban E., Imamura K., Luebbers R., and Kufe D. Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J. Clin. Invest. 81 (1988) 1506-1510
292. Schall T.J., Lewis M., Koller K.J., Lee A., Rice G.C., Wong G.H., Gatanaga T., Granger G.A., Lentz R., Raab H., Kohr W.J., and Groeddel D.J. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61 (1990) 361-370
293. Scheurich P., Thoma B., Ücer U., and Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNFα: Induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T cell responses. J. Immunol. 138 (1987) 1786-1790
294. Scheurich P., Köbrich G., and Pfizenmaier K. Antagonistic control of tumor necrosis factor receptors by protein kinases A and C. Enhancement of TNF receptor synthesis by protein kinase A and transmodulation of receptors by protein kinase C. J. Exp. Med. 170 (1989) 947-958
295. Scheurich P., Grell M., Meager A., and Pfizenmaier K. Agonistic and antagonistic antibodies as a tool to study the functional role of human tumor necrosis factor receptors. In: Fiers W., and Buurman W.A. (Eds). Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance (1993), Karger, New York 52-57
296. Schmid E., Müller T.H., Budzinski R.-M., Pfizenmaier K., and Binder K. Lymphocyte adhesion to human endothelial cells induces tissue factor expression via a juxtacrine pathway. Thromb. Haemost. 73 (1995) 421-428
297. Schulze-Osthoff K., Bakker A.C., Vanhaesebroeck B., Beyaert R., Jacob W.A., and Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J. Biol. Chem. 267 (1992) 5317-5323
298. Schulze-Osthoff K., Beyaert R., Vandevoorde V., Haegeman G., and Fiers W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J. 12 (1993) 3095-3104
299. Schütze S., Nottrott S., Pfizenmaier K., and Krönke M. Tumor necrosis factor signal transduction. Cell-type-specific activation and translocation of protein kinase C. J. Immunol. 144 (1990) 2604-2608
300. Schütze S., Berkovic D., Tomsing O., Unger C., and Krönke M. Tumor necrosis factor induces rapid production of 1′2′diacylglycerol by a phosphatidylcholine-specific phospholipase C. J. Exp. Med. 174 (1991) 975-988
301. Schütze S., Potthoff K., Machleidt T., Berkovic D., Wiegmann K., and Krönke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 71 (1992) 765-767
302. Schwarz H., Tuckwell J., and Lotz M. A receptor induced by lymphocyte activation (Ila)-A new member of the human nerve-growth-factor tumor-necrosis-factor receptor family. Gene 134 (1993) 295-298
303. Seckinger P., Zhang J.H., Hauptmann B., and Dayer J.M. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: Evidence of immunological cross-reactivity with the TNF receptor. Proc. Natl. Acad. Sci. USA 87 (1990) 5188-5192
304. Selmaj K.W., and Raine C.S. TNF mediated myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23 (1988) 339-346
305. Shalaby M.R., Sundan A., Loetscher H., Brockhaus M., Lesslauer W., and Espevik T. Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J. Exp. Med. 172 (1990) 1517-1520
306. Sherblom A.P., Decker J.M., and Muchmore A.V. The lectin-like interaction between recombinant tumor necrosis factor and uromodulin. J. Biol. Chem. 263 (1988) 5418-5424
307. Smith C.A., Davis T., Anderson D., Solam L., Beckmann M.P., Jerzy R., Dower S.K., Cosman D., and Goodwin R.G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248 (1990) 1019-1023
308. Smith M.R., Munger W.E., Kung H.F., Takacs L., and Durum S.K. Direct evidence for an intracellular role for tumor necrosis factor-alpha 1. Microinjection of tumor necrosis factor kills target cells. J. Immunol. 144 (1990) 162-169
309. Smith C.A., Davis T., Wignall J.M., Din W.S., Farrah T., Upton C., McFadden G., and Goodwin R.G. T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem. Biophys. Res. Commun. 176 (1991) 335-342
310. Smith C.A., Farrah T., and Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins-activation, costimulation, and death. Cell 76 (1994) 959-962
311. Smith R.A., and Baglioni C. The active form of tumor necrosis factor is a trimer. J. Biol. Chem. 262 (1987) 6951-6956
312. Smyth M.J., and Ortaldo J.R. Mechanisms of cytotoxicity used by human peripheral blood CD4+ and CD8+ T cell subsets. The role of granule exocytosis. J. Immunol. 151 (1993) 740-747
313. Song H.Y., Rothe M., and Goeddel D.V. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc. Natl. Acad. Sci. USA 93 (1996) 6721-6725
314. Suffys P., Beyaert R., Van Roy F., and Fiers W. Reduced tumour necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism. Biochem. Biophys. Res. Commun. 149 (1987) 735-743
315. Suffys P., Beyaert R., VanRoy F., and Fiers W. Involvement of a serine protease in tumour-necrosis-factor-mediated cytotoxicity. Eur. J. Biochem. 178 (1988) 257-265
316. Sugarman B.J., Aggarwal B.B., Hass P.E., Figari I.S., Palladino M.A., and Shepard H.M. Recombinant human tumor necrosis factor-α: Effects on proliferation of normal and transformed cells in vitro. Science 230 (1985) 943-945
317. Sung S.S., Jung L.K., Walters J.A., Chen W., Wang C.Y., and Fu S.M. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J. Exp. Med. 168 (1988) 1539-1551
318. Sung S.S., Bjorndahl J.M., Wang C.Y., Kao H.T., and Fu S.M. Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody. J. Exp. Med. 167 (1988) 937-953
319. + T lymphocyte plasma membrane. J. Exp. Med. 174 (1991) 755-759
320. Sypek J.P., Jacobson S., Vorys A., and Wyler D.J. Comparison of gamma interferon, tumor necrosis factor, and direct cell contact in activation of antimycobacterial defense in murine macrophages. Infect. Immun. 61 (1993) 3901-3906
321. Talmadge J.E. Synergy in the toxicity of cytokines: Preclinical studies. Int. J. Immunopharmacol. 14 (1992) 383-390
322. Tartaglia L.A., Weber R.F., Figari I.S., Reynolds C., Palladino Jr. M.A., and Goeddel D.V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA 88 (1991) 9292-9296
323. Tartaglia L.A., Ayres T.M., Wong G.H., and Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74 (1993) 845-853
324. Tartaglia L.A., Goeddel D.V., Reynolds C., Figari I.S., Weber R.F., Fendly B.M., and Palladino Jr. M.A. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J. Immunol. 151 (1993) 4637-4641
325. Tartaglia L.A., Pennica D., and Goeddel D.V. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem. 268 (1993) 18542-18548
326. Teng M.N., Park B.H., Koeppen H.K., Tracey K.J., Fendly B.M., and Schreiber H. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc. Natl. Acad. Sci. USA 88 (1991) 3535-3539
327. Thanhauser A., Reiling N., Bohle A., Toellner K.M., Duchrow M., Scheel D., Schluter C., Ernst M., Flad H.D., and Ulmer A.J. Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology 80 (1993) 151-156
328. Thoma B., Grell M., Pfizenmaier K., and Scheurich P. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J. Exp. Med. 172 (1990) 1019-1023
329. Tiegs G., Barsig J., Matiba B., Uhlig S., and Wendel A. Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice. J. Clin. Invest. 93 (1994) 2616-2622
330. +, class II MHC-restricted cytotoxic T cells. Immunology 71 (1990) 208-212
331. Tracey K.J. Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. Circ. Shock 35 (1991) 123-128
332. Tracey K.J., and Cerami A. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 9 (1993) 317-343
333. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., Milsark I.W., Hariri R.J., Fahey III T.J., Zentella A., and Alberts J.D. Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470-474
334. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., Lowry S.F., and Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330 (1987) 662-664
335. Trefzer U., Brockhaus M., Loetscher H., Parlow F., Budnik A., Grewe M., Christoph H., Kapp A., Schopf E., Luger T.A., and Krutmann J. The 55-kD tumor necrosis factor receptor on human keratinocytes is regulated by tumor necrosis factor-alpha and by ultraviolet B radiation. J. Clin. Invest. 92 (1993) 462-470
336. Tsujimoto M., Yip Y.K., and Vilcek J. Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. J. Immunol. 136 (1986) 2441-2444
337. Ücer U., Scheurich P., Bartsch H., Berkovic D., Ertel C., and Pfizenmaier K. Specific membrane receptors for human interferon-gamma (IFN-gamma). Behring Inst. Mitt. 81 (1987) 88-97
338. Ueno Y., Suzuki H., Kobayashi K., Miura M., and Toyota T. Production of tumor necrosis factor alpha and interleukin 1 beta by peripheral blood mononuclear cells from chronic hepatitis type C patients during interferon therapy. Tohoku J. Exp. Med. 161 (1990) 157-158
339. Unglaub R., Maxeiner B., Thoma B., Pfizenmaier K., and Scheurich P. Downregulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators. J. Exp. Med. 166 (1987) 1788-1797
340. Valone S.E., Rich E.A., Wallis R.S., and Ellner J.J. Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect. Immun. 56 (1988) 3313-3315
341. 60. J. Immunol. 153 (1994) 3043-3050
342. Van Lint J., Agostinis P., Vandevoorde V., Haegeman G., Fiers W., Merlevede W., and Vandenheede J.R. Tumor necrosis factor stimulates multiple serine/threonine protein kinases in Swiss 3T3 and L929 cells. Implication of casein kinase-2 and extracellular signal-regulated kinases in the tumor necrosis factor signal transduction pathway. J. Biol. Chem. 267 (1992) 25916-25921
343. Van Ostade X., Vandenabeele P., Everaerdt B., Loetscher H., Gentz R., Brockhaus M., Lesslauer W., Tavernier J., Brouckaert P., and Fiers W. Human TNF mutants with selective activity on the p55 Receptor. Nature 361 (1993) 266-269
344. Van Ostade X., Vandenabeele P., Tavernier J., and Fiers W. Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor. Eur. J. Biochem. 220 (1994) 771-779
345. Van Zee K.J., Stackpole S.A., Montegut W.J., Rogy M.A., Calvano S.E., Hsu K.C., Chao M., Meschter C.L., Loetscher H., Stuber D., Ettlin U., Wipf B., Lesslauer W., Lowry S.F., and Moldawer L.L. A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J. Exp. Med. 179 (1994) 1185-1191
346. Van Zee K.J., Moldawer L.L., Oldenburg H.S.A., Thompson W.A., Stackpole S.A., Montegut W.J., Rogy M.A., Meschter C., Gallati H., Schiller C.-D., Richter W.F., Loetscher H., Ashkenazi A., Chamow S.M., Wurm F., Calvano S.E., Lowry S.F., and Lesslauer W. Protection against Escherichia coli Bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-lg fusion protein, Ro 45-2081. J. Immunol. 156 (1996) 2221-2230
347. Voskuhl R.R., Martin R., Bergman C., Dalal M., Ruddle N.H., and McFarland H.F. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 15 (1993) 137-143
348. Waage A., Halstensen A., and Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 355-357
349. Waage A., and Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J. Exp. Med. 167 (1988) 1987-1992
350. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., and Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169 (1989) 333-338
351. Wallach D., Holtmann H., Engelmann H., and Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J. Immunol. 140 (1988) 2994-2999
352. Wang A.M., Creasey A.A., Ladner M.B., Lin L.S., Strickler J., Van Arsdell J.N., Yamamoto R., and Mark D.F. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228 (1985) 149-154
353. Warren M.K., and Ralph P. Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor, and colony stimulating activity. J. Immunol. 137 (1986) 2281-2285
354. Webb G.C., and Chaplin D.D. Genetic variability at the human tumor necrosis factor loci. J. Immunol. 145 (1990) 1278-1285
355. Wiegmann K., Schütze S., Kampen E., Himmler A., Machleidt T., and Krönke M. Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J. Biol. Chem. 267 (1992) 17997-18001
356. Wiegmann K., Schütze S., Machleidt T., Witte D., and Krönke M. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78 (1994) 1005-1015
357. Wiley S.R., Schooly K., Smolak P.J., Din W.S., Huang C.-P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., and Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
358. Williams R.O., Mason L.J., Feldmann M., and Maini R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 91 (1994) 2762-2766
359. Wilson A.G., di Giovine F.S., Blakemore A.I., and Duff G.W. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum. Mol. Genet. 1 (1992) 353
360. Wilson A.G., de Vries N., Pociot F., di Giovine F.S., van der Putte L.B., and Duff G.W. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med. 177 (1993) 557-560
361. Winzen R., Wallach D., Engelmann H., Nophar Y., Brakebusch C., Kemper O., Resch K., and Holtmann H. Selective decrease in cell surface expression and mRNA level of the 55-kDa tumor necrosis factor receptor during differentiation of HL-60 cells into macrophage-like but not granulocyte-like cells. J. Immunol. 148 (1992) 3454-3460
362. Winzen R., Wallach D., Kemper O., Resch K., and Holtmann H. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J. Immunol. 150 (1993) 4346-4353
363. Wisniewski H.G., Maier R., Lotz M., Lee S., Klampfer L., Lee T.H., and Vilcek J. TSG-6: A TNF-, IL-1-, and LPS-inducible secreted glycoprotein associated with arthritis. J. Immunol. 151 (1993) 6593-6601
364. Wong G.H., and Goeddel D.V. Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism. Science 242 (1988) 941-944
365. Wong G.H., Krowka J.F., Stites D.P., and Goeddel D.V. In vitro anti-human immunodeficiency virus activities of tumor necrosis factor-alpha and interferon-gamma. J. Immunol. 140 (1988) 120-124
366. Wong G.H., Elwell J.H., Oberley L.W., and Goeddel D.V. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell. 58 (1989) 923-931
367. Wong G.H., Tartaglia L.A., Lee M.S., and Goeddel D.V. Antiviral activity of tumor necrosis factor is signaled through the 55-kDa type I TNF receptor. J. Immunol. 149 (1992) 3350-3353
368. Wood P.R., and Clark I.A. Macrophages from babesia and malaria infected mice are primed for monokine release. Parasite-Immunol. 6 (1984) 309-317
369. Woods K.M., and Chapes S.K. Three distinct cell phenotypes of induced-TNF cytotoxicity and their relationship to apoptosis. J. Leuk. Biol. 53 (1993) 37-44
370. Wooley P.H., Dutcher J., Widmer M.B., and Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type-II collagen-induced arthritis in mice. J. Immunol. 151 (1993) 6602-6607
371. Wright S.C., Kumar P., Tam A.W., Shen N., Varma M., and Larrick J.W. Apoptosis and DNA fragmentation precede TNF-induced cytolysis in U937 cells. J. Cell. Biochem. 48 (1992) 344-355
372. Yamauchi N., Kuriyama H., Watanabe N., Neda H., Maeda M., and Niitsu Y. Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res. 49 (1989) 1671-1675
373. Yang Z., Costanzo M., Golde D.W., and Kolesnick R.N. Tumor necrosis factor activation of the sphingomyelin pathway signals nuclear factor kappa B translocation in intact HL-60 cells. J. Biol. Chem. 268 (1993) 20520-20523
374. Yokota S., Geppert T.D., and Lipsky P.E. Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha. J. Immunol. 140 (1988) 531-536
375. Zechner R., Newman T.C., Sherry B., Cerami A., and Breslow J.L. Recombinant human cachectin/tumor necrosis factor but not interleukin-1 alpha downregulates lipoprotein lipase gene expression at the transcriptional level in mouse 3T3-L1 adipocytes. Mol. Cell. Biol. 8 (1988) 2394-2401
376. Zhang Y.H., Lin J.X., and Vilcek J. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol. Cell. Biol. 10 (1990) 3818-3823